Jiangsu Hengrui Pharmaceuticals Co 600276.SS · CNY
Health Care · Pharmaceuticals · Shanghai · 🇨🇳 China
49.23
-2.38%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jiangsu Hengrui Pharmaceuticals Co
Its shares trade on Shanghai under the ticker 600276.SS. It has been listed since 18 October 2000. In the fiscal year to 31 December 2025, it reported revenue of CN¥31.43bn and net income of CN¥7.71bn. At that date it held total assets of CN¥69.87bn and shareholders' equity of CN¥61.27bn.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs. The company is headquartered in Lianyungang, Jiangsu. The company went IPO on 2000-10-18. The firm's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Oct 2000
- Employees
- 20,636
- Website
- hengrui.com ↗
Leadership
Pay as last reported
- Mr. Piaoyang SunChairman of the Board, since 1997CN¥1.6m
- Mr. Hongbin DaiPresident, General Manager, Director, since 2003CN¥3.8m
- Mr. Jianjun LiuChief Financial OfficerCN¥2.2m
- Mr. Ningjun JiangExecutive Vice President, Director, since 2023CN¥2.3m
- Mr. Lianshan ZhangExecutive Vice President, Director, since 2010CN¥3.3m
- Mr. Jieping SunSenior Vice President, Director, since 2003CN¥2.4m
- Mr. Feng HeDeputy General ManagerCN¥2.5m
- Mr. Cheng LiaoDeputy General ManagerCN¥2.3m
- Mr. Yun LuDeputy General Manager
- Mr. Yaping ShenDeputy General ManagerCN¥2.0m
- Mr. Quanren WangDeputy General ManagerCN¥2.3m
- Mr. Xuejian XuDeputy General Manager
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 87
- Environment
- 99
- Social
- 99
- Governance
- 64
- Direct emissions (scope 1)
- 8,516.6 t
- Energy emissions (scope 2)
- 249,380.64 t
- Women in the workforce
- 44.9%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jiangsu Hengrui Pharmaceuticals employs 20,636 full-time employees in Lianyungang, China.
- The company's main products include antineoplastic drugs and angiomyocardiac drugs.
- Jiangsu Hengrui Pharmaceuticals distributes its products domestically and internationally.
Weaknesses
- The company's business is limited to the pharmaceutical sector in China.
- Jiangsu Hengrui Pharmaceuticals has no presence in the Financials sector.
- The firm's products are primarily focused on domestic market sales.
Opportunities
- Jiangsu Hengrui Pharmaceuticals can expand its international market reach.
- The company can leverage its expertise in antineoplastic drugs for new markets.
- Jiangsu Hengrui Pharmaceuticals has potential to grow in the Health Care sector.
Threats
- The company faces competition from other pharmaceutical firms in China.
- Jiangsu Hengrui Pharmaceuticals must navigate regulatory changes in the Health Care industry.
- The firm's reliance on domestic market sales poses a risk for international market fluctuations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.